Jaap Verweij - Concepedia

Author

Jaap Verweij

Rotterdam University of Applied Sciences

Also Known As

J VERWEIJ, J Verweij, J. VERWEIJ, J. Verweij, J. W. M. Verweij, J. W. Verweij, J.W.M. Verweij, JAAP VERWEIJ, Jaap Verweij, John Smyth

885

Publications

70.3K

Citations

114

H-Index

226

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC Erasmus MC Cancer Institute European Organisation for Research and Treatment of Cancer Erasmus University Rotterdam

About

Jaap Verweij is an author at Rotterdam University of Applied Sciences specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	22	31	18K
2	Engineering	5	5	240
3	Arts	1	1	113
4	Education	1	1	34
5	Language Studies	1	1	34

Jaap Verweij

434

Publications

58.6K

Citations

104

H-Index

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, The Lancet Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer Treatment	2006	2.6K
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Allan T. van Oosterom, Ian Judson, Jaap Verweij, The Lancet OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment	2001	1.3K
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Ian Judson, Jaap Verweij, Hans Gelderblom, The Lancet Oncology Metastatic Soft-tissue SarcomaVersus Intensified DoxorubicinOncologyMalignant DiseasePathology	2014	1.1K
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, European Journal of Cancer OncologyGastrointestinal OncologyMedicineKit MutationsDose Selection	2006	893
Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, Cancer Research	2009	780
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors Johanna C. Bendell, Jordi Rodón, Howard A. Burris, Journal of Clinical Oncology	2011	679
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai, Journal of Clinical Oncology OncologyAngiogenesisBone Sarcoma GroupSoft Tissue SarcomaPharmacology	2009	674
New guidelines to evaluate the response to treatment in solid tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Breast Cancer Solid TumorsMedicineCancer ManagementNew GuidelinesCancer Treatment	2005	662
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study Rolf D. Issels, Lars H. Lindner, Jaap Verweij, The Lancet Oncology Surgical OncologyRegional HyperthermiaMalignant DiseaseMedicineRandomised Phase 3	2010	649

Page 1